Skip to search boxSkip to navigationSkip to main content

Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

  • Farhad Ravandi(corresponding author)
    ,
  • Jeffrey L. Jorgensen
    ,
  • Susan M. O'Brien
    ,
  • Elias Jabbour
    ,
  • Deborah A. Thomas
    ,
  • Gautam Borthakur
*Corresponding author for this work
  • University of Texas MD Anderson Cancer Center
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Abstract

<p>The prognostic value of minimal residual disease (MRD) assessed by multi-parameter flow cytometry (MFC) was investigated among 340 adult patients with B-cell acute lymphoblastic leukaemia (B-ALL) treated between 2004 and 2014 using regimens including the hyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine) backbone. Among them, 323 (95%) achieved complete remission (CR) and were included in this study. Median age was 52 years (range, 15-84). Median white blood cell count (WBC) was 9·35 × 10<sup>9</sup>/l (range, 0·4-658·1 ×1 0<sup>9</sup>/l). MRD by MFC was initially assessed with a sensitivity of 0·01%, using a 15-marker, 4-colour panel and subsequently a 6-colour panel on bone marrow specimens obtained at CR achievement and at approximately 3 month intervals thereafter. MRD negative status at CR was associated with improved disease-free survival (DFS) and overall survival (OS) (P = 0·004 and P = 0·03, respectively). Similarly, achieving MRD negative status at approximately 3 and 6 months was associated with improved DFS (P = 0·004 and P < 0·0001, respectively) and OS (P = 0·004 and P < 0·0001, respectively). Multivariate analysis including age, WBC at presentation, cytogenetics (standard versus high risk) and MRD status at CR, 3 and 6 months, indicated that MRD negative status at CR was an independent predictor of DFS (P < 0·05). Achievement of an MRD negative state assessed by MFC is an important predictor of DFS and OS in adult patients with ALL.</p>

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 392-400 (9 pages)

Journal (Volume, Issue Number)

British Journal of Haematology (Volume 172, Issue 3)

Publication milestones

  • Published - 02/01/2016

Publication status

Published - 02/01/2016

ISSN

0007-1048

Publication IDs

  • Scopus: 84955727108
  • PubMed: 26492205
  • ORCID: /0000-0002-8636-1071/work/68811140

Publication metrics

Metrics

Scopus
citations
SciVal
citations
70
SciVal
FWCI
3.92
SciVal
Author count
22
SciVal
Paper percentile
97
SciVal
Top percentile
5
Fractional count
1
Fractional count
0.05
Fractional count
21
Fractional count
0.95
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Citation count
108
Mentions
1
Social media
11
Captures
96

Funding Details

FunderFunding number
NCI
P30CA016672